Although we could identify de novo pathogenic single-nucleotide variations (SNV) in bona fide breast cancer drivers [Functional analysis through Hidden Markov Models (FATHMM) >0.6; refs. 20, 21], none has been previously linked to ET resistance (i.e., FGFR2 S702 L; refs. 14–16; Supplementary Fig. S3A and Supplementary Table S1; refs. 15–17). This evidence concerns the gene FGFR2 and breast carcinoma.